Clin2
NCT07115043Possibly a fitRecruiting

Study of AZD6750 for advanced solid tumors

MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)Renal Cell CarcinomaMerkel Cell CarcinomaTriple Negative Breast CancerHead and Neck Squamous Cell CarcinomaGastric Cancer/Gastroesophageal Junction Cancer

Treatments studied

Part of Cancer, Digestive system, Infections, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
120 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years old or older.
  • You are able to walk and take care of yourself (ECOG score 0 or 1).
  • You have at least one tumor that can be measured on a scan.
  • You have a stored tumor sample from a previous biopsy or surgery.
  • Your cancer has spread or cannot be removed by surgery, and you have one of the specific types listed.
  • You have not had certain past treatments or medical conditions (such as severe autoimmune disease or brain metastases that are not stable).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06295432Recruiting· Phase 2
Study of two targeted drugs for EGFR-mutated lung cancer

This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.

Guangzhou, Guangdong
NCT05123482Recruiting· Phase 1/Phase 2
Early study of AZD8205 for advanced solid tumors

This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.

Duarte, California
NCT06551142Recruiting· Phase 1
Study of GSK5764227 for advanced solid tumors

This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.

Stanford, California
NCT06219941Recruiting· Phase 2
Studying AZD0901 for Claudin18.2-positive advanced solid tumors

This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.

Orange, California
NCT07438782Recruiting· Phase 1
Study of a new drug for advanced solid tumors

This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.

Philadelphia, Pennsylvania
NCT05417594Recruiting· Phase 1/Phase 2
Targeted drug study for advanced cancers with genetic changes

This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.

La Jolla, California

Hear when a new Melanoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.